Guillaume Cartron, MD, PhD

Head of Hematology Department
Centre Hospitalier Universitaire de Montpellier, France

Poster(s):

• 1413 - A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 ICLL-07 FILO trial

• 1424 - Safety Analysis of Fixed-Duration Acalabrutinib-Venetoclax Combinations vs Chemoimmunotherapy: A Post Hoc Analysis From the Phase 3 AMPLIFY Trial